BETHESDA, Md.--(BUSINESS WIRE)--BrainScope Company, Inc., a privately held neurotechnology company with an initial focus on traumatic brain injury (TBI) and concussion assessment, announced today that Michael Singer, Chief Executive Officer, will present at the 27th Annual Piper Jaffray Healthcare Conference in New York City. He is scheduled to present at 8:50 a.m. EST on Wednesday, December 2.
BrainScope is a medical neurotechnology company that is developing a new generation of hand-held, easy-to-use, non-invasive instruments designed to aid medical professionals in rapidly and objectively assessing various neurological conditions. The Company has received approximately $28 million of Department of Defense contracts and is backed by Revolution (created by AOL co-founder Steve Case), Shaman Ventures, ZG Ventures, State of Maryland Venture Fund, Brain Trust Accelerator Fund, and Difference Capital. BrainScope devices in development are based on a proprietary technology platform, which integrates databases of brainwave recordings with advanced digital signal processing, sophisticated algorithms, miniaturized hardware and disposable headset sensors. BrainScope's unique devices are being created to meet a long-standing clinical need for improved early identification and triage of head injured patients. The Company holds 92 issued and pending patents on its technology. In May 2015 the United States Food and Drug Administration (FDA) cleared the company’s Ahead 200 device, which uses commercial smartphone hardware leveraging Google’s Android operating system and a custom sensor to record and analyze a patient’s electroencephalogram (EEG) after head injury. BrainScope devices under development, including the Ahead 300 and the Ahead Concussion Assessment System, for assessment of traumatically-induced structural head injury and concussion are for investigational use only. For more information, please visit www.brainscope.com.